ClinicalTrials.Veeva

Menu

Triosephosphate Isomerase Level in Relation to Rheumatoid Aerthritis Activity and Structural Damage

A

Assiut University

Status

Not yet enrolling

Conditions

Rheumatoid Arthritis

Treatments

Diagnostic Test: serum TPI

Study type

Observational

Funder types

Other

Identifiers

NCT07105566
TPI level in RA patients

Details and patient eligibility

About

  1. Assess the serum level of TPI in patients with RA compared to healthy controls.
  2. Correlate serum level of TPI and disease activity.
  3. Correlation of serum TPI level with US7 damage index

Full description

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent synovial inflammation, synovial hyperplasia, and progressive destruction of bone and cartilage. These pathological processes can lead to joint deformities and loss of function, significantly affecting patients' quality of life. In addition to joint damage, RA often manifests with extraarticular complications involving the cardiovascular, pulmonary, and other organ systems. These systemic effects impose a substantial burden on patients' physical and mental well-being, as well as their socioeconomic status .The disease often affects subjects between the ages of 40 and 70; however, it can also occur at a younger age. Globally, the prevalence rate of RA is approximately 1%, with females experiencing a higher incidence . Triosephosphate isomerase (TPI) is a metabolic enzyme that regulates the flow of glycolysis and energy generation by converting dihydroxyacetone phosphate (DHAP) into D- glyceraldehyde 3-phosphate (G3P). TPI is one of the glycolytic enzymes implicated in the pathogenesis of RA.

Additionally, it has been shown to possess functions beyond glycolysis, including potential roles in the nucleus related to cancer pathogenesis and chemotherapy resistance . Some studies showed a significant correlation between elevated TPI levels and RA, with TPI serving as an independent predictor of the disease. With some findings, which include a high sensitivity of 98.5% and specificity of 100%, suggest that TPI could be a valuable biomarker for the early diagnosis and management of RA

Enrollment

70 estimated patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with RA who fulfill 2010 ACR/EULAR classification criteria

Exclusion criteria

  1. Individuals with uncontrolled chronic diseases such as hypertension , diabetes, heart disease, liver or kidney disease, other autoimmune disorders and tumors.
  2. Pregnant women.
  3. Rheumatologic diseases other than RA

Trial design

70 participants in 2 patient groups

cases
Description:
Rheumatoid Arthritis pateints
Treatment:
Diagnostic Test: serum TPI
controls
Description:
healthy controls
Treatment:
Diagnostic Test: serum TPI

Trial contacts and locations

0

Loading...

Central trial contact

Nada Mohsen

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems